We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
51
Assembly Biosciences
ASMB
$700M
$8.73M 0.07%
20,833
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$1.98B
$8.59M 0.07%
128,666
– –
SYRS
53
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.46M 0.07%
57,484
– –
ACHN
54
DELISTED
Achillion Pharmaceuticals
ACHN
$8.34M 0.07%
1,856,637
– –
CFRX
55
DELISTED
ContraFect Corporation
CFRX
$7.94M 0.06%
8,941
+3,884
+77% +$3.67M
CBIO
56
Crescent Biopharma
CBIO
$637M
$7.88M 0.06%
5,633
– –
NBRV
57
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.68M 0.06%
3,753
+2,353
+168% +$5.52M
ALKS icon
58
Alkermes
ALKS
$8.11B
$7.64M 0.06%
150,251
– –
GWPH
59
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.61M 0.06%
+75,000
New +$8.03M
VNDA icon
60
Vanda Pharmaceuticals
VNDA
$319M
$7.59M 0.06%
+423,884
New +$7.09M
DMTX
61
DELISTED
Dimension Therapeutics, Inc
DMTX
$7.51M 0.06%
1,251,881
– –
STML
62
DELISTED
Stemline Therapeutics, Inc.
STML
$7.03M 0.06%
633,497
– –
MGNX icon
63
MacroGenics
MGNX
$261M
$6.72M 0.05%
363,676
– –
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$857M
$6.4M 0.05%
251,888
– –
TTPH
65
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.39M 0.05%
+46,750
New +$6.25M
FSTX
66
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.28M 0.05%
93,286
– –
XLRN
67
DELISTED
Acceleron Pharma
XLRN
$6.12M 0.05%
163,900
+135,135
+470% +$4.69M
GNMX
68
DELISTED
Aevi Genomic Medicine Inc
GNMX
$5.73M 0.05%
4,546,426
+2,928,337
+181% +$3.74M
SYRE icon
69
Spyre Therapeutics
SYRE
$9.39B
$5.61M 0.05%
45,515
– –
LJPC
70
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.38M 0.04%
154,675
-350,057
-69% -$11.3M
RNAC icon
71
Cartesian Therapeutics
RNAC
$304M
$5.29M 0.04%
9,660
– –
VYGR icon
72
Voyager Therapeutics
VYGR
$209M
$4.88M 0.04%
+237,014
New +$2.67M
EPZM
73
DELISTED
Epizyme, Inc
EPZM
$4.43M 0.04%
232,481
– –
CMTA
74
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$4.22M 0.03%
+250,000
New +$4.09M
ALBO
75
DELISTED
Albireo Pharma Inc
ALBO
$4.19M 0.03%
200,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2017 Portfolio in Review

As of Q3 2017, Julian Baker held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Julian Baker added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Julian Baker's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Julian Baker fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Julian Baker's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Julian Baker opened 9 new positions and closed 9 in Q3 2017.
  • Julian Baker's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.